Agent for the treatment of alopecia

Abstract

It is an object of the present invention to provide a new agent for the treatment of alopecia, the agent being not only effective and safe for, in particular, alopecia areata, androgenetic alopecia in a male, androgenetic alopecia in a female, female pattern alopecia, postpartum alopecia, seborrheic alopecia, alopecia pityroides, senile alopecia, cancer chemotherapy drug-induced alopecia, and alopecia due to radiation exposure, but also effective for a target having resistance to treatment with minoxidil or finasteride, there being no side effects such as an itching sensation, irritation, or feminization, and no contraindications, the agent suppressing dandruff or having a therapeutic effect for white hair, and the therapeutic effect for alopecia being maintained for a long period even when use of the agent is stopped. The solution means of the present invention is an agent for the treatment of alopecia containing as an active ingredient a C-type natriuretic peptide (CNP), a B-type natriuretic peptide (BNP), a derivative of these NPs, a chimeric peptide of these NPs, or a derivative of a chimeric peptide of these NPs.

1 . An agent for the treatment of alopecia comprising as an active ingredient a C-type natriuretic peptide (CNP) or a B-type natriuretic peptide (BNP). 
     
     
         2 . The agent for the treatment of alopecia according to  claim 1 , wherein it is for the treatment of alopecia areata, androgenetic alopecia, seborrheic alopecia, alopecia pityroides, female pattern alopecia, postpartum alopecia, senile alopecia, cancer chemotherapy drug-induced alopecia, or alopecia due to radiation exposure. 
     
     
         3 . The agent for the treatment of alopecia according to  claim 1 , wherein the C-type natriuretic peptide (CNP) or the B-type natriuretic peptide (BNP) is a CNP derivative or a BNP derivative. 
     
     
         4 . The agent for the treatment of alopecia according to  claim 1 , wherein the C-type natriuretic peptide (CNP) or the B-type natriuretic peptide (BNP) is a chimeric peptide of CNP or BNP, said chimeric peptide forming a cyclic structure by an intramolecular disulfide bond,
 the CNP is a peptide selected from the group consisting of CNP-22, CNP-53, a peptide containing any amino acid sequence having 5 or more contiguous amino acids from the CNP-22 amino acid sequence in which any 1 to 5 amino acids have been deleted, substituted, or added, and a peptide containing any amino acid sequence having 5 or more contiguous amino acids from the CNP-53 amino acid sequence in which any 1 to 5 amino acids have been deleted, substituted, or added,   the BNP is a peptide selected from the group consisting of BNP-26, BNP-32, BNP-45, a peptide containing any amino acid sequence having 5 or more contiguous amino acids from the BNP-26 amino acid sequence in which any 1 to 5 amino acids have been deleted, substituted, or added, a peptide containing any amino acid sequence having 5 or more contiguous amino acids from the BNP-32 amino acid sequence in which any 1 to 5 amino acids have been deleted, substituted, or added, and a peptide containing any amino acid sequence having 5 or more contiguous amino acids from the BNP-45 amino acid sequence in which any 1 to 5 amino acids have been deleted, substituted, or added, and   said chimeric peptide has CNP activity or BNP activity, or the C-type natriuretic peptide (CNP) or the B-type natriuretic peptide (BNP) is a derivative of the chimeric peptide.   
     
     
         5 . The agent for the treatment of alopecia according to  claim 1 , wherein it further comprises at least one medicinal agent selected from the group consisting of betamethasone, clobetasol, gentamicin, carpronium chloride, and minoxidil. 
     
     
         6 . The agent for the treatment of alopecia according to  claim 1 , wherein it is an agent for the prevention or treatment of white hair, an agent for the prevention or treatment of vellus hair formation, or an agent for inhibiting seborrheic scalp or the occurrence of dandruff. 
     
     
         7 . The agent for the treatment of alopecia according to  claim 2 , wherein the androgenetic alopecia is androgenetic alopecia in a male or androgenetic alopecia in a female. 
     
     
         8 . The agent for the treatment of alopecia according to  claim 7 , wherein the hair loss site is the frontal region or the crown. 
     
     
         9 . The agent for the treatment of alopecia according to  claim 2 , wherein there is coexisting seborrheic alopecia or alopecia pityroides. 
     
     
         10 . The agent for the treatment of alopecia according to  claim 2 , wherein the alopecia areata is normal alopecia areata, alopecia totalis, alopecia universalis, or alopecia ophiasis. 
     
     
         11 . The agent for the treatment of alopecia according to  claim 1 , wherein the alopecia is alopecia of a target having a history of, or coexisting, allergic disease or autoimmune disease. 
     
     
         12 . The agent for the treatment of alopecia according to  claim 10 , wherein the autoimmune disease is any of chronic discoid lupus erythematosus, localized scleroderma, pemphigus, pemphigoid, herpes gestationis, linear IgA bullous dermatosis, acquired epidermolysis bullosa, vitiligo, Sutton's nevus, an autoimmune thyroid disease, systemic lupus erythematosus, rheumatoid arthritis, or myasthenia gravis. 
     
     
         13 . The agent for the treatment of alopecia according to  claim 1 , wherein the alopecia is alopecia of a target having a history of, or coexisting, allergic disease or alopecia of a target having a history of, or coexisting, atopic disease. 
     
     
         14 . The agent for the treatment of alopecia according to  claim 1 , wherein the alopecia is alopecia accompanied by erythema, scale, or crust. 
     
     
         15 . The agent for the treatment of alopecia according to  claim 1 , wherein the alopecia is alopecia of a target having a history of, or coexisting, allergic dermatitis or allergic rhinitis. 
     
     
         16 . The agent for the treatment of alopecia according to  claim 1 , wherein the alopecia is alopecia of a target showing an allergic reaction toward at least one allergen selected from the group consisting of house dust, mite, cedar, Dactylis, ragweed, and cat fur. 
     
     
         17 . The agent for the treatment of alopecia according to  claim 1 , wherein the alopecia is alopecia of a target showing an allergic reaction toward at least one allergen selected from the group consisting of house dust, mite, cedar, Dactylis, ragweed, and cat fur in an allergen test by any of a scratch test, an intradermal test, a patch test, and a specific IgE antibody in vitro assay. 
     
     
         18 . The agent for the treatment of alopecia according to  claim 1 , wherein the alopecia is alopecia exhibiting resistance to treatment with a steroid drug, an antihistamine drug, Glycyron (registered trademark), carpronium chloride, cepharanthin, minoxidil, finasteride, cyclosporin A, Keishikaryukotsuboreito, Hangekobokuto, biotin, Anthralin, local immunotherapy, cooling therapy, linearly polarized near-infrared ray irradiation therapy, PUVA therapy, or tacrolimus. 
     
     
         19 . The agent for the treatment of alopecia according to  claim 1 , wherein the alopecia is alopecia of a target that has attained a steroid-dependent state or a target for which a steroid treatment agent cannot be used. 
     
     
         20 . The agent for the treatment of alopecia according to  claim 2 , wherein the alopecia areata is S1 or B0 alopecia or above. 
     
     
         21 . The agent for the treatment of alopecia according to  claim 1 , wherein a therapeutic effect is obtained by application for 1 week or longer. 
     
     
         22 . The agent for the treatment of alopecia according to  claim 1 , wherein there is no recurrence for a period of 1 month or longer even when application is stopped. 
     
     
         23 . The agent for the treatment of alopecia according to  claim 1 , wherein the dosage form is an ointment, a gel, a cream, a lotion, a liquid, a wax, a powder, a spray, a gel spray, a foam, a shampoo, a treatment, a scalp treatment, or a tonic. 
     
     
         24 . The agent for the treatment of alopecia according to  claim 1 , wherein the content of the C-type natriuretic peptide (CNP) or the B-type natriuretic peptide (BNP) is 1 to 1000 μg/g. 
     
     
         25 . The agent for the treatment of alopecia according to  claim 1 , wherein it further comprises at least one medicinal agent selected from the group consisting of a steroid drug, an antihistamine drug, a vasodilator, a male hormone activity inhibitor, a female hormone drug, an antibiotic, an antifungal agent, pentadecane, cytopurine (6-benzylaminopurine), t-flavanone, adenosine, cepharanthin, Glycyron (registered trademark), which is a complex of glycyrrhizin, methionine, and glycine, cyclosporin A, Keishikaryukotsuboreito, Hangekobokuto, biotin, Anthralin, tacrolimus, and a tricyclic antidepressant.